查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1433351

全球生物标记临床阶段外包服务市场2023-2030

Global Biomarker Clinical Phase Outsourcing Services Market 2023-2030
出版日期: | 出版商: Orion Market Research | 英文 210 Pages | 商品交期: 2-3个工作天内

价格

全球生物标记临床阶段外包服务市场预计在预测期内（2023-2030年）CAGR为21.3%。药物开发过程数量的增加以及癌症、心血管疾病和神经系统疾病等慢性疾病盛行率的上升等重要因素导致人们越来越关注用于早期检测、疾病监测和治疗反应评估的生物标记。世界卫生组织 (WHO) 估计每年有 1790 万人丧生。此外，根据美国癌症协会的数据，2020年全球估计有1,810万新发癌症病例和990万癌症死亡病例。据预测，由于吸烟率上升、不良饮食习惯和缺乏运动等因素，未来几年癌症负担将会增加。生物标誌物显示各种健康或疾病特征。

细分市场前景

全球生物标记临床阶段外包服务市场按类型、治疗领域和最终用户进行细分。根据类型，市场分为预测生物标记、预后生物标记、安全生物标记和替代终点。根据治疗领域，市场细分为肿瘤学、心臟病学、神经学和自体免疫疾病。此外，根据最终用户，市场分为製药公司和生技公司。其中，替代端点子细分市场预计将占据相当大的市场份额。替代终点是具有良好特征的生物标记的一小部分，具有经过充分评估的临床相关性。该细分市场的成长归因于合约研究人员在开髮用于诊断和监测几种慢性疾病的替代终点方面的投资不断增加。

预计心臟病学细分市场将在全球生物标记临床阶段外包服务市场中占据相当大的份额

在治疗领域中，心臟病学细分市场预计将在全球生物标记临床阶段外包服务市场中占据相当大的份额。细分市场的成长归因于冠状动脉疾病、心臟衰竭、瓣膜性心臟病的盛行率不断增加，以及对冠状动脉临床试验和技术进步的需求不断增长。英国心臟基金会（BHF）2023年1月公布的资料报告称，2021年最常见的心血管疾病包括冠心病（缺血性）心臟病（2019年全球患病率估计为2亿）、外周动脉（血管）疾病（1.1亿） 、中风（1亿）和心房颤动（6000万）。此外，报告也显示，北美、欧洲、非洲和中东、拉丁美洲、亚洲和澳洲的心臟病和循环系统疾病盛行率分别为4,800万、1亿、9,800万、4,800万和3.4亿。

区域展望

全球生物标记临床阶段外包服务市场根据地理位置进一步细分，包括北美（美国和加拿大）、欧洲（英国、义大利、西班牙、德国、法国和欧洲其他地区）、亚太地区（印度、中国） 、日本、韩国和亚洲其他地区）以及世界其他地区（中东和非洲以及拉丁美洲）。其中，由于癌症盛行率不断上升，越来越多的西方製药公司将其製造活动外包到印度和中国等新兴经济体，预计亚太地区将在全球市场中占据显着份额。推动亚太地区生物标誌物临床阶段外包服务市场。

北美地区预计全球生物标记临床阶段外包服务市场将以显着的CAGR成长

在所有地区中，预计北美在预测期内将以相当大的CAGR成长。市场成长归因于北美地区心血管疾病数量的增加，预计将对未来几年临床试验市场的成长产生积极影响。根据美国心臟协会 (AHA) 的数据，心血管疾病仍然是美国的首要死因，2020 年导致 928,741 人死亡。美国癌症协会估计，到 2023 年，预计将诊断出超过 190 万个新癌症病例在美国。预计 2023 年美国将有约 609,820 人死于癌症，即每天约 1,670 人死亡。此外，由于有专门从事生物标记临床阶段外包服务的成熟合约研究组织，例如全球临床试验、Caidya、ICON plc 等。由于在临床研究中引入了多项创新、突破性技术并提供了最先进的基础设施，该地区正在进行大量心臟病临床试验。根据 ClinicalTrials.gov 的数据，截至 2023 年 9 月，约 5,068 个持久性生物标记临床阶段外包服务在美国註册。

市场参与者展望

服务于全球生物标记临床阶段外包服务市场的主要公司包括 Celerion、Fujirebio Europe NV、ICON plc 和 Parexel International Corp. 等。市场参与者透过各种策略（包括併购、合作、合作、融资和新产品发布），为市场成长做出了巨大贡献，以保持市场竞争力。例如，2023 年 3 月，医疗保健技术公司 Koneksa Health Inc. 扩大了与生命科学咨询公司 SSI Strategy 的合作，以扩大基于证据的数位生物标记在临床试验中的采用。 Koneksa 的数位生物标记解决方案包括一个平台，该平台允许研究赞助商和临床站点完美地即时汇总来自患者日记、设备、ePRO 和临床评估的资料，以提供个人健康状况的完整视图。

报告涵盖

目录

第 1 章：报告摘要

  • 目前行业分析及成长潜力展望
  • 研究方法和工具
  • 市场区隔
    • 按细分
    • 按地区

第 2 章：市场概述与见解

  • 报告范围
  • 分析师见解和当前市场趋势
    • 主要发现
    • 建议
    • 结论

第 3 章：竞争格局

  • 主要公司分析
  • Celerion
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • Fujirebio Europe NV
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • ICON plc
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • Parexel International Corp.
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • 关键策略分析

第 4 章：市场细分

  • 按类型分類的全球生物标记临床阶段外包服务市场
    • 预测性生物标记
    • 预后生物标记
    • 安全生物标记
    • 代理端点
  • 按治疗领域分類的全球生物标记临床阶段外包服务市场
    • 肿瘤学
    • 心臟病学
    • 神经病学
    • 自体免疫疾病
  • 以最终用途分類的全球生物标记临床阶段外包服务市场
    • 製药公司
    • 生技公司

第 5 章：区域分析

  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 义大利
    • 西班牙
    • 法国
    • 欧洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 世界其他地区

第 6 章：公司简介

  • Charles River Laboratories International, Inc.
  • Eurofins Scientific corp.
  • GenScript ProBio Biotech Corp.
  • GHO Capital Partners LLP
  • Laboratory Corporation of America (R) Holdings
  • NorthEast BioAnalytical Laboratories LLC
  • Proteome Sciences plc
  • Thermo Fisher Scientific Inc.
  • WuXi AppTec Co., Ltd.
  • Zymewire (Division of Lumerate Inc.)
Product Code: OMR2028015

Global Biomarker Clinical Phase Outsourcing Services Market Size, Share & Trends Analysis Report by Type (Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers, and Surrogate Endpoints), by Therapeutic Area (Oncology, Cardiology, Neurology, and Autoimmune Diseases), and by End-Use (Pharmaceutical Companies and Biotechnology Companies), Forecast Period (2023-2030)

The global biomarker clinical phase outsourcing services market is anticipated to grow at a CAGR of 21.3% during the forecast period (2023-2030). Significant factors including the increasing number of drug development processes, and the rising prevalence of chronic diseases such as cancer, cardiovascular diseases, and neurological disorders has led to an increased focus on biomarkers for early detection, disease monitoring, and treatment response assessment. World Health Organization (WHO) estimated 17.9 million lives every year. Furthermore, according to the American Cancer Society, in 2020, there were an estimated 18.1 million new cancer cases and 9.9 million cancer deaths globally. It is projected that the burden of cancer would increase in coming years as a result of factors including the rising rates of smoking, poor eating habits, and inactivity. Biomarkers indicate a variety of health or disease characteristics.

Segmental Outlook

The global biomarker clinical phase outsourcing services market is segmented on the type, therapeutic area, and end-user. Based on the type, the market is sub-segmented into predictive biomarkers, prognostic biomarkers, safety biomarkers, and surrogate endpoints. Based on the therapeutic area, the market is sub-segmented into oncology, cardiology, neurology, and autoimmune diseases. Further, based on end-user, the market is bifurcated into pharmaceutical companies and biotechnology companies. Among the type, the surrogate endpoints sub-segment is anticipated to hold a considerable share of the market. Surrogate endpoints are a small subset of well-characterized biomarkers with well-evaluated clinical relevance. The segmental growth is attributed to the increasing investment by contract researchers in developing surrogate endpoints for the diagnosis and monitoring of several chronic ailments.

Cardiology Sub-Segment is Anticipated to Hold a Considerable Share of the Global Biomarker Clinical Phase Outsourcing Services Market

Among the therapeutic area, the cardiology sub-segment is expected to hold a considerable share of the global biomarker clinical phase outsourcing services market. The segmental growth is attributed to the increasing prevalence of coronary artery disease, heart failure, valvular heart disease, coupled with the rising demand for coronary artery clinical trials and technical advancement. The British Heart Foundation (BHF) data published in January 2023 reported that in 2021, the most common cardiovascular conditions includes coronary (ischemic) heart disease (global prevalence estimated at 200 million in 2019), peripheral arterial (vascular) disease (110 million), stroke (100 million) and atrial fibrillation (60 million). Additionally, the report revealed that the prevalence of heart and circulatory diseases was 48 million, 100 million, 98 million, 48 million and 340 million in North America, Europe, Africa and the Middle East, Latin America, and Asia & Australia.

Regional Outlook

Global biomarker clinical phase outsourcing services market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, the Asia-Pacific region is anticipated to hold a prominent share of the market around the globe, owing to the increasing prevalence of cancers, increasing number of Western pharmaceutical companies outsourcing their manufacturing activities in emerging economies such as India, and China are driving the biomarker clinical phase outsourcing services market in the Asia Pacific.

The North America Region is Expected to Grow at a Significant CAGR in the Global Biomarker Clinical Phase Outsourcing Services Market

Among all the regions, North America is anticipated to grow at a considerable CAGR over the forecast period. The market growth is attributed to the increasing number of cardiovascular disorders across the North America is estimated to positively impact the clinical trials market growth in upcoming years. According to the American Heart Association (AHA), CVDs remains as the leading cause of death in the US, accounted for 928,741 deaths in the year 2020. American Cancer Society, estimated in 2023, over 1.9 million new cancer cases are expected to be diagnosed in the US. Approximately 609,820 deaths from cancer are expected in the US in 2023, which is about 1,670 deaths per day. Additionally, owing to the presence of established contract research organizations specializing in biomarker clinical phase outsourcing services, such as global clinical trials, Caidya, ICON plc, and several others. Owing to the introduction of several innovative, ground-breaking technologies in clinical research and the provision of state-of-the-art infrastructure, numerous clinical trials for heart disorders are being performed across the region. As per Clinicaltrials.gov, as of September 2023, around 5,068 enduring biomarker clinical phase outsourcing services are registered in the US.

Market Players Outlook

The major companies serving the global biomarker clinical phase outsourcing services market include Celerion, Fujirebio Europe NV, ICON plc, and Parexel International Corp., among others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in March 2023, healthcare technology firm Koneksa Health Inc., expanded collaboration with life sciences consulting firm SSI Strategy to scale evidence-based digital biomarker adoption in clinical trials. The digital biomarker solutions of Koneksa include a platform which allows research sponsors and clinical sites to impeccably aggregate data, in real-time, from patient diaries, devices, ePROs, and clinical assessments, to deliver a complete view of a person's health.

The Report Covers

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global biomarker clinical phase outsourcing services market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. Celerion
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Fujirebio Europe NV
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. ICON plc
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Parexel International Corp.
    • 3.5.1. Overview
    • 3.5.2. Financial Analysis
    • 3.5.3. SWOT Analysis
    • 3.5.4. Recent Developments
  • 3.6. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Biomarker Clinical Phase Outsourcing Services Market by Type
    • 4.1.1. Predictive Biomarkers
    • 4.1.2. Prognostic Biomarkers
    • 4.1.3. Safety Biomarkers
    • 4.1.4. Surrogate Endpoints
  • 4.2. Global Biomarker Clinical Phase Outsourcing Services Market by Therapeutic Area
    • 4.2.1. Oncology
    • 4.2.2. Cardiology
    • 4.2.3. Neurology
    • 4.2.4. Autoimmune Diseases
  • 4.3. Global Biomarker Clinical Phase Outsourcing Services Market by End-Use
    • 4.3.1. Pharmaceutical Companies
    • 4.3.2. Biotechnology Companies

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Charles River Laboratories International, Inc.
  • 6.2. Eurofins Scientific corp.
  • 6.3. GenScript ProBio Biotech Corp.
  • 6.4. GHO Capital Partners LLP
  • 6.5. Laboratory Corporation of America® Holdings
  • 6.6. NorthEast BioAnalytical Laboratories LLC
  • 6.7. Proteome Sciences plc
  • 6.8. Thermo Fisher Scientific Inc.
  • 6.9. WuXi AppTec Co., Ltd.
  • 6.10. Zymewire (Division of Lumerate Inc.)

LIST OF TABLES

  • 1. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 2. GLOBAL PREDICTIVE BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 3. GLOBAL PROGNOSTIC BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL SAFETY BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 5. GLOBAL SURROGATE ENDPOINTS BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 6. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY THERAPEUTIC AREA, 2022-2030 ($ MILLION)
  • 7. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES IN ONCOLOGY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 8. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES IN CARDIOLOGY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 9. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES IN NEUROLOGY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 10. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES IN AUTOIMMUNE DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 11. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY END-USE, 2022-2030 ($ MILLION)
  • 12. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES FOR PHARMACEUTICAL COMPANIES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 13. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES FOR BIOTECHNOLOGY COMPANIES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 14. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 15. NORTH AMERICAN BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 16. NORTH AMERICAN BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 17. NORTH AMERICAN BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY THERAPEUTIC AREA, 2022-2030 ($ MILLION)
  • 18. NORTH AMERICAN BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY END-USE, 2022-2030 ($ MILLION)
  • 19. EUROPEAN BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 20. EUROPEAN BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 21. EUROPEAN BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY THERAPEUTIC AREA, 2022-2030 ($ MILLION)
  • 22. EUROPEAN BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY END-USE, 2022-2030 ($ MILLION)
  • 23. ASIA-PACIFIC BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 24. ASIA-PACIFIC BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 25. ASIA-PACIFIC BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY THERAPEUTIC AREA, 2022-2030 ($ MILLION)
  • 26. ASIA-PACIFIC BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY END-USE, 2022-2030 ($ MILLION)
  • 27. REST OF THE WORLD BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 28. REST OF THE WORLD BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 29. REST OF THE WORLD BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY THERAPEUTIC AREA, 2022-2030 ($ MILLION)
  • 30. REST OF THE WORLD BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY END-USE, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SHARE BY TYPE, 2022 VS 2030 (%)
  • 2. GLOBAL PREDICTIVE BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SHARE, 2022 VS 2030 (%)
  • 3. GLOBAL PROGNOSTIC BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL SAFETY BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 5. GLOBAL SURROGATE ENDPOINTS BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 6. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SHARE BY THERAPEUTIC AREA, 2022 VS 2030 (%)
  • 7. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES IN ONCOLOGY MARKET SHARE, 2022 VS 2030 (%)
  • 8. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES IN CARDIOLOGY MARKET SHARE, 2022 VS 2030 (%)
  • 9. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES IN NEUROLOGY MARKET SHARE, 2022 VS 2030 (%)
  • 10. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES IN AUTOIMMUNE DISEASES MARKET SHARE, 2022 VS 2030 (%)
  • 11. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET RESEARCH AND ANALYSIS BY END-USE, 2022 VS 2030 (%)
  • 12. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES FOR PHARMACEUTICAL COMPANIES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 13. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES FOR BIOTECHNOLOGY COMPANIES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 14. GLOBAL BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 15. US BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SIZE, 2022-2030 ($ MILLION)
  • 16. CANADA BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SIZE, 2022-2030 ($ MILLION)
  • 17. UK BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SIZE, 2022-2030 ($ MILLION)
  • 18. FRANCE BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SIZE, 2022-2030 ($ MILLION)
  • 19. GERMANY BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SIZE, 2022-2030 ($ MILLION)
  • 20. ITALY BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. SPAIN BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. REST OF EUROPE BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. INDIA BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. CHINA BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SIZE, 2022-2030 ($ MILLION)
  • 25. JAPAN BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SIZE, 2022-2030 ($ MILLION)
  • 26. SOUTH KOREA BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SIZE, 2022-2030 ($ MILLION)
  • 27. REST OF ASIA-PACIFIC BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SIZE, 2022-2030 ($ MILLION)
  • 28. REST OF THE WORLD BIOMARKER CLINICAL PHASE OUTSOURCING SERVICES MARKET SIZE, 2022-2030 ($ MILLION)